Trial Profile
An Open Label, Multicenter, Phase II Study of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients Harboring T790M Mutation Who Failed EGFR TKIs and With Brain and/or Leptomeningeal Metastasis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Aug 2021 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 08 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2020 Results, analysis of data cut-off as of August 31st, 2019 assessing efficacy of 160 mg Osimertinib, published in the Annals of Oncology